蛋白磷酸酶2A抑癌因子在非小细胞肺癌组织中的表达及其对预后的影响  

Expression of Cancerous Inhibitor of Protein Phosphatase 2A in Non-Small Cell Lung Cancer on Prognosis

作　　者：闫睿[1] 罗洞波[1] 刘艳萍[1] 于婵娟[1] YAN Rui LUO Dongbo LIU Yanping YU Chanjuan(Department of Anesthesiology, Tumor Hospital, Xinjiang Medical University, Urumqi, Xinjiang 830011, China)

机构地区：[1]新疆医科大学附属肿瘤医院,新疆乌鲁木齐830011

出　　处：《新疆大学学报（自然科学版）》2017年第2期213-217,共5页Journal of Xinjiang University(Natural Science Edition)

基　　金：新疆维吾尔自治区自然科学基金青年项目(2014211C120)

摘　　要：目的探讨蛋白磷酸酶2A抑癌因子(CIP2A)在非小细胞肺癌(NSCLC)中的表达及其对预后的影响.方法选择2010年6月～2011年5月,收治的106例NSCLC患者,均在医院进行手术切除治疗.本方案经新疆医科大学附属肿瘤医院伦理委员会批准,所有患者和家属签署知情同意书.手术切除癌组织和匹配的癌旁无瘤组织.用免疫组织化学和图像分析技术检测上述病理标本中CIP2A蛋白的表达情况.随访3年,生存时间按月计算,总体生存时间计算从手术日期到死亡或未次随访日期;无瘤生存时间的截止点以术后首次CT、超声、核磁等影像学证实肿瘤复发或转移.失访病例和非肿瘤原因死亡病例按统计学要求以截尾数据处理.观察CIP2A蛋白的表达情况与患者生存率的关系,用统计学方法对影响预后的因素进行相关性分析.结果其中男性75例,女性31例,年龄:26～85岁,平均(64.18±10.33)岁,体重指数(22.13±1.35)kg﹒m2.106例患者中,有10例失访,剩余96例患者完成研究,随访率为85.71%.截至末次随访时间,43例(44.79%)患者死于原发性肿瘤,53例(55.21%)继续存活.按TNM分期分期,I期患者43例,II期患者30例,IIIa患者期18例,IIIb患者期13例,IV期患者2例.腺癌45例,鳞癌38例,大细胞癌10例,腺鳞癌13例.在癌组织标本中高表达23例,中表达31例,低表达21例,21例无表达,表达率为78.13%;在癌旁正常组织低表达31例,无表达65例,表达率为32.29%.CIP2A的蛋白表达在癌组织中显著高于相应癌旁组织(P<0.05);CIP2A高表达患者3年总生存率和3年无瘤生存率均显著低于低表达的患者(P<0.05).单因素分析显示,CIP2A蛋白表达与3年总生存率密切相关;多因素分析显示,CIP2A蛋白表达不是3年生存率的独立影响因素.结论 CIP2A蛋白在NSCLC组织中高表达,且阳性表达患者的3年总生存率和3年无瘤生存率均显著低于阴性表达患者,但是多因素分析结果显示,CIP2A不是NSCLC患者预后的独立�Objective To investigate the protein expressions and clinical significance of cancerous inhibitor of protein phosphatase 2A （CIP2A） in non-small cell lung cancer （NSCLC） and its prognostic impact,provide a new theoretical foundation for NSCLC clinical diagnosis and prognosis.Methods One hundred and six cases of patients with NSCLC were selected from June 2010 to May 2011,given surgical removal of the cancerous tissue and matched paracarcinoma tissues.The program approved by the Xinjiang Medical University Affiliated Cancer Hospital Ethics Committee,all patients and their families signed informed consent.The protein expressions of CIP2A in pathological samples above-mentioned were detected by immunohistochemical and computer image analysis.The correlations between the expression level of CIP2A protein and survival rates of patients were observed by three years following up.The influent factors of prognostic were analyzed by Statistical methods.Results 75 males and 31 females,aged：26 to 85 years,mean （64.18 ＆#177; 10.33） years,body mass index （22.13 ＆#177; 1.35） kg.m2.Among 106 patients,10 patients were lost,the remaining 96 patients completed the study,follow-up rate was 85.71%.At the time of the last follow-up,43 patients （44.79%） died of primary tumors and 53 （55.21%） survived.According to TNM staging,43 patients with stage Ⅰ,30 patients with stage Ⅱ,18 patients with Ⅲa,13 patients with Ⅲb,and 2 patients with stage Ⅳ.Adenocarcinoma in 45 cases,squamous cell carcinoma in 38 cases,10 cases of large cell carcinoma,adenosquamous carcinoma in 13 cases.The expression rate was 78.13%,31 cases were low in normal tissues and 65% in the normal tissues,the expression rate was 32.29%,and the expression rate was 32.29%.Compared with near-cancer NSCLC normal tissue,the protein expression of CIP2A in cancerous tissue was higher （P〈0.05）.Three years total survival and three years disease free survival of patients with CIP2A over-expression were significantly higher than patients wit

关 键 词：蛋白磷酸酶2A抑癌因子 非小细胞肺癌 抑癌因子 

分 类 号：C642.0[社会学]